1. Compilation group of China cardiovascular health and disease report . Report on cardiovascular health and disease in China 2019: an updated summary. Chin Circulation J 2020; 35: 833–854.
Google Scholar2. Shen, L, Chunyu, Y, Chenfei, R, et al. Appropriateness of coronary revascularization in patients with stable coronary artery disease: a multicenter clinical trial. Chin Circulation J 2019; 34: 859–865.
Google Scholar3. Virani, SS, Alonso, A, Benjamin, EJ, et al. Heart disease and stroke statistics – 2020 update: a report from the American Heart Association. Circulation 2020; 141: e139–e596.
Google Scholar | Crossref | Medline4. Pfisterer, M, Buser, P, Osswald, S. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. Acc Current J Rev 2003; 12: 11–11.
Google Scholar | Crossref5. Hueb, W, Lopes, NH, Gersh, BJ, et al. Five-year follow-up of the medicine, angioplasty, or surgery study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007; 115: 1082–1089.
Google Scholar | Crossref | Medline6. Kalay, N, Ozdogru, I. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA 2007; 298: 1985–1991.
Google Scholar | Crossref | Medline7. Moroi, M, Yamashina, A, Tsukamoto, K, et al. Coronary revascularization does not decrease cardiac events in patients with stable ischemic heart disease but might do in those who showed moderate to severe ischemia. Int J Cardiol 2012; 158: 246–252.
Google Scholar | Crossref | Medline8. Shawa, LJ, Maron, DJ, Hartigan, PM, et al. Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. Am Heart J 2012; 164: 243–250.
Google Scholar | Crossref | Medline9. Nishigaki, K, Yamazaki, T, Kitabatake, A, et al. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease: a randomized, comparative, multicenter study. JACC Cardiovasc Interv 2008; 1: 469–479.
Google Scholar | Crossref | Medline10. BARI 2D Study Group , Frye, RL, August, P, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503–2515.
Google Scholar | Crossref | Medline11. Al-Lamee, R, Thompson, D, Dehbi, HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 2018; 391: 31–40.
Google Scholar | Crossref | Medline12. Steg, PG, Greenlaw, N, Tendera, M, et al. Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease. JAMA Intern Med 2014; 174: 1651–1659.
Google Scholar | Crossref | Medline13. Knuuti, J, Wijns, W, Saraste, A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41: 407–477.
Google Scholar | Crossref14. Maron, DJ, Hochman, JS, Reynolds, HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med 2020; 382: 1395–1407.
Google Scholar | Crossref | Medline15. Marcos-Garces, V, Gavara, J, Monmeneu, JV, et al. Vasodilator stress CMR and all-cause mortality in stable ischemic heart disease: a large retrospective registry. JACC Cardiovasc Imaging 2020; 13: 1674–1686.
Google Scholar | Crossref | Medline16. Shaw, LJ, Berman, DS, Picard, MH, et al. Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. JACC Cardiovasc Imaging 2014; 7: 593–604.
Google Scholar | Crossref | Medline17. Jørgensen, L, Paludan-Müller, AS, Laursen, DR, et al. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews. Syst Rev 2016; 5: 80.
Google Scholar | Crossref | Medline18. Wells, G . The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. In: Symposium on systematic reviews: beyond the basics, Catherine’s college, Oxford, 2014.
Google Scholar19. Li, J, Yang, X, Tian, Y, et al. Complete revascularization determined by myocardial perfusion imaging could improve the outcomes of patients with stable coronary artery disease, compared with incomplete revascularization and no revascularization. J Nucl Cardiol 2019; 26: 944–953.
Google Scholar | Crossref | Medline20. Yoda, S, Hori, Y, Hayase, M, et al. Correlation between early revascularization and major cardiac events demonstrated by ischemic myocardium in Japanese patients with stable coronary artery disease. J Cardiol 2017; 71: 44–51.
Google Scholar | Crossref | Medline21. Boiten, HJ, van den Berge, JC, Valkema, R, et al. Ischemia burden on stress SPECT MPI predicts long-term outcomes after revascularization in stable coronary artery disease. J Nucl Cardiol 2018; 25: 958–966.
Google Scholar | Crossref | Medline22. Carvajal-Juarez, I, Espínola-Zavaleta, N, Antonio-Villa, NE, et al. Optimal medical treatment or invasive approach in patients with significantly obstructive coronary artery disease and ischemia. Arch Med Res 2020; 51: 413–418.
Google Scholar | Crossref | Medline23. Simonsen, JA, Mickley, H, Johansen, A, et al. Outcome of revascularisation in stable coronary artery disease without ischaemia: a Danish registry-based follow-up study. BMJ Open 2017; 7: e016169.
Google Scholar | Crossref | Medline24. Sharir, T, Hollander, I, Hemo, B, et al. Survival benefit of coronary revascularization after myocardial perfusion SPECT: the role of ischemia. J Nucl Cardiol 2021; 28: 1676–1687.
Google Scholar | Crossref | Medline25. Hachamovitch, R, Hayes, SW, Friedman, JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003; 107: 2900–2907.
Google Scholar | Crossref | Medline26. Neumann, FJ, Sousa-Uva, M, Ahlsson, A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87–165.
Google Scholar | Crossref27. Laukkanen, JA, Kunutsor, SK. Revascularization versus medical therapy for the treatment of stable coronary artery disease: A meta-analysis of contemporary randomized controlled trials. Int J Cardiol 2021; 324: 13–21.
Google Scholar | Crossref | Medline28. Bangalore, S, Maron, DJ, Stone, GW, et al. Routine revascularization versus initial medical therapy for stable ischemic heart disease: a systematic review and meta-analysis of randomized trials. Circulation 2020; 142: 841–857.
Google Scholar | Crossref | Medline29. Katritsis, DG, Mark, DB, Gersh, BJ. Revascularization in stable coronary disease: evidence and uncertainties. Nat Rev Cardiol 2018; 15: 408–419.
Google Scholar | Crossref | Medline30. Montalescot, G, Sechtem, U, Achenbach, S, et al. 2013 ESC guidelines on the management of stable coronary artery disease. Russ J Cardiol 2014; 7: 7–79.
Google Scholar31. Davies, RF, Goldberg, A, Forman, S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997; 95: 2037–2043.
Google Scholar | Crossref | Medline